RVU — Ryvu Therapeutics SA Share News
0.000.00%
Last trade - 00:00- PLN319.98m
- PLN332.91m
- PLN62.25m
Brief: Ryvu Therapeutics Initiates Four Phase II Clinical Trials For RVU120
Brief: Ryvu Therapeutics Announces Dosing of the First Patient in the POTAMI-61 Phase II Study of RVU120 for the Treatment of Patients with Myelofibrosis (MF)
Brief: Ryvu Therapeutics Says Starts Phase II Study Of RVU120 For Myelofibrosis
Brief: Ryvu Therapeutics's Project On Recommendation List For 3.1 Mln Zloty Subsidy
Brief: Ryvu Therapeutics Q3 Net Loss 26.6 Mln Zlotys
Brief: Ryvu Therapeutics Signs EUR 3.8 Mln Deal For JASPIS-01 Clinical Trial
Brief: Ryvu Therapeutics Performed Dosing Of First Patient In Remark Phase II Study Of RVU120
Brief: Ryvu Theraputics Q2 Net Loss At 30.4 Mln Zlotys
Brief: Ryvu Therapeutics To Continue Development Of PRMT5 Programme
Brief: Ryvu Therapeutics Secures EUR 6 Mln Financing From EIB
Brief: Ryvu Therapeutics To Get EUR 8 Mln Of Financing From EIB
Brief: Ryvu Therapeutics Obtains Status Of Associate Partner Within IPCEI Med4Cure
Brief: Ryvu Therapeutics Signs Max. 10.3 Mln Zloty Funding Deal With NCBR
Brief: Ryvu Therapeutics Q1 Net Loss Widens To 19.4 Mln Zlotys
Brief: Ryvu Therapeutics Says Its Project Recommended For Funding By Poland's PARP
Brief: Ryvu Therapeutics FY Net Loss Widens To 92.1 Mln Zlotys
Brief: Ryvu Therapeutics To Get EUR 8 Mln Of Financing From EIB
Brief: Ryvu Therapeutics Reaches Second Milestone Under License Agreement With Exelixis
Brief: Ryvu Therapeutics Q3 Net Loss Widens To 18.3 Mln Zlotys